| Bid | 3.06 |
| Market Cap | 385.38M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.46 |
| PE Ratio (ttm) | -5.18 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 11 |
| Volume | 57,547 |
| Avg. Volume (20D) | 149,614 |
| Open | 8.15 |
| Previous Close | 8.06 |
| Day's Range | 7.35 - 8.40 |
| 52-Week Range | 4.42 - 18.40 |
| Beta | undefined |
About ENGN
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calm...
Analyst Forecast
According to 9 analyst ratings, the average rating for ENGN stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 296.83% from the latest price.
2 weeks ago · businesswire.com
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene...
2 months ago · businesswire.com
enGene to Participate in Guggenheim's Inaugural Healthcare Innovation ConferenceBOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimoge...
2 months ago · businesswire.com
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene...
